Company intelligence / Profile preview

Kolon TissueGene, Inc.

Rockville, Maryland, United States

Ownership: Public · 950160
Employees: ~57
Development stage: Phase 3

Overview

Kolon TissueGene’s lead product TG-C/Invossa has demonstrated efficacy in reducing pain and improving function for osteoarthritis of the knee. The company has completed Phase II clinical trials in the US and plans to initiate Phase III studies. Invossa has been commercialized outside the US but faced regulatory challenges previously; current focus remains on advancing through late-stage clinical development for broader approval.

Therapeutic areas: OtherImmunologyNeurologyRheumatology
Modalities: Cell therapy (allogeneic cell therapy)Gene therapyRegenerative medicine
Industry: Biotech

Drug pipeline

6 assets

TissueGene-C

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Kolon TissueGene, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kolon TissueGene, Inc..

Explore the full profile